search
Back to results

Fluid Resuscitation in Patients Suffering From Burns Injury

Primary Purpose

Burns

Status
Terminated
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Volulyte
Human Serum Albumin
Sponsored by
Fresenius Kabi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Burns

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients ≥18 years of age
  • 15%≥ Burn Total Body Surface Area Injury ≤60%
  • Signed written informed consent from patient or legal representative

Exclusion Criteria:

  • Patient age >80 years
  • Delay of patient randomisation >8 hours post-burn
  • Known pregnancy
  • Known renal failure with oliguria or anuria not related to hypovolaemia (e.g. patients receiving dialysis treatment)
  • High voltage electrical conduction injury
  • Known severe liver disease
  • Known fluid overload (hyperhydration), especially in cases of pulmonary oedema and congestive cardiac failure
  • Intracranial bleeding (known active or suspicion of intracranial bleeding)

Sites / Locations

  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Volulyte

Human Serum Albumin

Arm Description

Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)

5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)

Outcomes

Primary Outcome Measures

Cumulative fluid balance (input-output)

Secondary Outcome Measures

Cumulative fluid balance (input-output)
Oedema monitoring: patient's weight, circumference measurement of unburned limb
Urine output
Haemodynamics
Bladder pressure
Use of vasoactive and inotropic drugs

Full Information

First Posted
September 18, 2012
Last Updated
June 25, 2014
Sponsor
Fresenius Kabi
search

1. Study Identification

Unique Protocol Identification Number
NCT01689506
Brief Title
Fluid Resuscitation in Patients Suffering From Burns Injury
Official Title
Prospective Randomised Controlled Open-label Explorative Multi-centre Pilot Trial of Volulyte®-Supplemented Versus Albumin-supplemented Fluid Resuscitation for Major Burns
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Terminated
Why Stopped
Study stopped due to low recruitment
Study Start Date
December 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fresenius Kabi

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This clinical study compares two fluid resuscitation treatments in patients suffering from burns injury. The treatments are Volulyte® and Human Serum Albumin (HSA) which will be administered as infusion solutions. It will be evaluated whether Volulyte® is effective and safe, and provides any benefit.
Detailed Description
Severe burns injury presents a unique resuscitation problem due to simultaneous loss of electrolyte and protein-rich exudate from the burn wound itself and leakage of fluid and protein from the circulation into the interstitial compartment. In the post shock phase of burn resuscitation, patients frequently suffer oedema of unburned tissues and organs and a positive fluid balance of many litres. This pilot study will compare two burns fluid resuscitation regimes (supplementation with 6% HES 130/0.4 in an isotonic electrolyte solution, Volulyte 6%, versus supplementation with Human Serum Albumin, HSA 50g/L) on patient outcome with particular regard to fluid balance at 24 hours after burns injury (primary variable).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Burns

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Volulyte
Arm Type
Experimental
Arm Description
Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
Arm Title
Human Serum Albumin
Arm Type
Active Comparator
Arm Description
5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
Intervention Type
Drug
Intervention Name(s)
Volulyte
Other Intervention Name(s)
6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution
Intervention Description
6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
Intervention Type
Drug
Intervention Name(s)
Human Serum Albumin
Intervention Description
5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
Primary Outcome Measure Information:
Title
Cumulative fluid balance (input-output)
Time Frame
at 24 hours after burns injury
Secondary Outcome Measure Information:
Title
Cumulative fluid balance (input-output)
Time Frame
at 8 hours after burns injury, at 24 hours after randomisation, and until day 7 after burns injury
Title
Oedema monitoring: patient's weight, circumference measurement of unburned limb
Time Frame
once daily until day 7 after burns injury
Title
Urine output
Time Frame
hourly until 24 hours after burns injury, at 24 hours after randomization and, thereafter, once daily until day 7 after burns injury
Title
Haemodynamics
Time Frame
hourly until 24 hours after burns injury, at 24 hours after randomization and, thereafter, 4 times daily until day 7 after burns injury
Title
Bladder pressure
Time Frame
once daily until day 7 after burns injury
Title
Use of vasoactive and inotropic drugs
Time Frame
until 24 hours after randomisation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients ≥18 years of age 15%≥ Burn Total Body Surface Area Injury ≤60% Signed written informed consent from patient or legal representative Exclusion Criteria: Patient age >80 years Delay of patient randomisation >8 hours post-burn Known pregnancy Known renal failure with oliguria or anuria not related to hypovolaemia (e.g. patients receiving dialysis treatment) High voltage electrical conduction injury Known severe liver disease Known fluid overload (hyperhydration), especially in cases of pulmonary oedema and congestive cardiac failure Intracranial bleeding (known active or suspicion of intracranial bleeding)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naiem Moiemen, PhD MD
Organizational Affiliation
Plastic and Burns Department, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre
City
Birmingham
ZIP/Postal Code
B15 2WB
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Fluid Resuscitation in Patients Suffering From Burns Injury

We'll reach out to this number within 24 hrs